Reboxetine
- Generic Name
- Reboxetine
- Drug Type
- Small Molecule
- Chemical Formula
- C19H23NO3
- CAS Number
- 71620-89-8
- Unique Ingredient Identifier
- 947S0YZ36I
- Background
Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
- Indication
For the treatment of clinical depression.
- Associated Conditions
- Major Depressive Disorder (MDD)
- Associated Therapies
- Maintenances
Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment
- Conditions
- Cognitive Performance in Major Depression
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Zentrum für Integrative Psychiatrie
- Target Recruit Count
- 45
- Registration Number
- NCT00993876
- Locations
- 🇩🇪
Zentrum für Integrative Psychiatrie, Kiel, Germany
Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation
- Conditions
- Cerebral Stroke
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 12
- Registration Number
- NCT00853866
- Locations
- 🇩🇪
University Hospital Hamburg-Eppendorf, Department of Neurology, Hamburg, HH, Germany
Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study
- Conditions
- Depression
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2007-01-25
- Lead Sponsor
- Geha Mental Health Center
- Target Recruit Count
- 60
- Registration Number
- NCT00426946
- Locations
- 🇮🇱
Tel Aviv Community Mental Helath Center, Tel Aviv, Israel
Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 35
- Registration Number
- NCT00421369
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2006-12-08
- Lead Sponsor
- Abarbanel Mental Health Center
- Target Recruit Count
- 30
- Registration Number
- NCT00409201
- Locations
- 🇮🇱
Abarbanel Medical Mental Health Center, Bat Yam, Israel
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
- Conditions
- Major DepressionPainAbdominal Pain
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-05-27
- Target Recruit Count
- 42
- Registration Number
- NCT00209807
- Locations
- 🇪🇸
Hospital Universitari vall d'Hebron, Barcelona, Catalonia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.